Comparison of Standard Dose Alectinib to Alectinib in Adjusted Dose Based on Alectinib Bloodlevels
Status:
Recruiting
Trial end date:
2026-12-31
Target enrollment:
Participant gender:
Summary
The ADAPT ALEC randomized controlled trial (RCT) is performed in patients with Anaplastic
Lymphoma Kinase (ALK) positive non-small cell lung cancer (NSCLC). The RCT will compare the
use of Therapeutic Drug Monitoring (TDM) and dose increases if alectinib 35 ng/Ml (arm A)
with standard of care (arm B).
Phase:
Phase 4
Details
Lead Sponsor:
University Medical Center Groningen
Collaborators:
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) Erasmus Medical Center Leiden University Medical Center Maastricht University Medical Center Radboud University Medical Center The Netherlands Cancer Institute